News >

Novel Combination Shows Promising Responses in Pancreatic Cancer

Silas Inman @silasinman
Published: Sunday, Nov 12, 2017

Zev Wainberg, MD

Zev Wainberg, MD
The combination of the novel tumor-associated macrophage (TAM)-targeting agent cabiralizumab and the PD-1 inhibitor nivolumab (Opdivo) resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer, according to findings from a phase I study presented at the 2017 SITC Annual Meeting.

Efficacy findings were presented solely for patients with pancreatic cancer at the SITC meeting, although adverse events (AEs) were described across the full study. The pancreatic cancer cohort contained 33 patients treated in the dose expansion stage of the study. The median age was 64 years, 58% had ECOG PS of 1, and 45% had received ≥3 prior regimens.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication